What is HC Wainwright’s Estimate for FDMT Q2 Earnings?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.04) per share for the quarter, up from their prior forecast of ($1.10). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($3.79) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($4.08) EPS, FY2027 earnings at ($4.40) EPS, FY2028 earnings at ($4.04) EPS, FY2029 earnings at ($2.65) EPS and FY2030 earnings at ($1.45) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.

Several other equities research analysts also recently issued reports on FDMT. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a report on Friday. Finally, Barclays started coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price for the company. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $10.34 on Wednesday. 4D Molecular Therapeutics has a 52-week low of $3.02 and a 52-week high of $12.34. The stock’s 50-day simple moving average is $9.42 and its 200 day simple moving average is $9.48. The company has a market cap of $540.58 million, a P/E ratio of -4.02 and a beta of 2.77.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. raised its holdings in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after buying an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of 4D Molecular Therapeutics by 164.4% during the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after acquiring an additional 2,882,508 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 4.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after acquiring an additional 174,489 shares during the last quarter. State Street Corp grew its position in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after buying an additional 1,785,106 shares during the last quarter. Finally, Armistice Capital LLC increased its stake in shares of 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after buying an additional 840,000 shares during the period. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.